Interestingly, selective inhibitors against p300/CBP, namely CCS1477 has been shown to inhibit the AR transcription program and is currently being evaluated in clinical trials for metastatic castration resistance prostate cancer (NCT03568656). This evidence concerns the gene AR and prostate carcinoma.